Next-gen mpox treat­ments: FDA calls for di­verse, ran­dom­ized con­trolled tri­als

For com­pa­nies look­ing to de­vel­op the next mpox (for­mer­ly known as mon­key­pox) an­tivi­rals, the FDA came out with new draft guid­ance yes­ter­day spelling out the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER